Methods: This was an interim analysis of the CA Clinics Observational Study investigating self-reported adverse events (AEs) and changes in health-related quality of life (HRQoL) outcomes over time after commencing
medicinal cannabis. Patients were prescribed
medicinal cannabis by a medical practitioner, containing various ratios of Δ9-tetrahydrocannabinol (
THC) and/or
cannabidiol (CBD).
Results: The overall
chronic pain cohort, and specifically the balanced CBD:
THC products, were associated with significantly reduced
pain intensity scores (p = 0.003, p = 0.025), with 22% of patients reporting a clinically meaningful reduction in
pain intensity. Patients in the
arthritis subset (n = 199) reported significantly reduced
pain intensity scores (p = 0.005) overall, and specifically for those taking CBD-only (p = 0.018) and balanced products (p = 0.005). Other HRQoL outcomes, including
pain interference and
pain impact scores were significantly improved depending on the CBD:
THC ratio. Products that contained a balanced ratio of CBD:
THC were associated with improvements in the most number of PROMIS-29 domains. Approximately half (n = 364; 51%) of the
chronic pain cohort experienced at least one AE, the most common being dry mouth (24%),
somnolence (19%) or
fatigue (12%). These findings were similar in the
arthritis subset.
Discussion: